ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia
Matthew S. Davids(Dana-Farber Cancer Institute), Othman Al‐Sawaf(Integrated Oncology (United States)), M. Porro Lurà(Roche (Switzerland)), Kavita Sail(AbbVie (United States)), Inhye E. Ahn(Dana-Farber Cancer Institute), Madhavi Pai(AbbVie (United States)), Kirsten Fischer(Düsseldorf University Hospital), Brenda Chyla(AbbVie (United States)), Sandra Robrecht(University of Cologne), Viktor Komlósi, John C. Pesko(AbbVie (United States)), Michael Hallek(Integrated Oncology (United States)), Jennifer R. Brown(Dana-Farber Cancer Institute), Can Zhang(Guizhou Normal University), Wendy Sinai(AbbVie (United States))
Cited by 12
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k